193rd ENMC International workshop Pathology diagnosis of idiopathic inflammatory myopathies 30 November - 2 December 2012, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 23, Issue 11, 2013, Pages 945-951

  De Bleecker, Jan L ^a   Lundberg, Ingrid E ^b   De Visser, Marianne ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; STEROID;

ANTISYNTHETASE SYNDROME; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DYSFERLINOPATHY; HISTIOCYTIC INFLAMMATORY MYOPATHY; HISTOPATHOLOGY; HUMAN; IMMUNE MYOPATHY WITH ENDOMYSIAL PATHOLOGY; IMMUNE MYOPATHY WITH PERIMYSIAL PATHOLOGY; IMMUNE POLYMYOPATHY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INCLUSION BODY MYOSITIS; INFLAMMATORY INFILTRATE; INFLAMMATORY MYOPATHY WITH VACUOLES AGGREGATES AND MITOCHONDRIAL PATHOLOGY; INTERNATIONAL COOPERATION; JUVENILE DERMATOMYOSITIS; MACROPHAGE; MEDICAL RESEARCH; MICROSCOPY; MUSCLE BIOPSY; MYOSITIS; NECROTIZING AUTOIMMUNE MYOPATHY; NETHERLANDS; POLYMYOSITIS; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; STATIN INDUCED NECROTIZING MYOPATHY;

BIOPSY; HUMANS; MYOSITIS; NETHERLANDS;

EID: 84884983123     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.07.007     Document Type: Article

References (31)

1. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
2. Dimachki M.M. Idiopathic inflammatory myopathies. J Neuroimmunol 2011, 231:32-42.
3. Dalakas M.C. Pathogenesis and therapies of immune-mediated myopathies. Autoimm Rev 2012, 11:203-206.
4. Van der Meulen M.F., Bronner I.M., Hoogendijk J.E., et al. Polymyositis: an overdiagnosed entity. Neurology 2003, 61:316-321.
5. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., Senecal J.L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005, 84:231-249.
6. Bohan A., Peter J. Polymyositis and dermatomyositis. N Engl J Med 1975, 292:344-347.
7. Christopher-Stine L. Neurologists are from Mars, rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2010, 22:623-626.
8. Hewer E., Goebel H.H. Myopathology of non-infectious inflammatory myopathies - the current status. Pathol Res Pract 2008, 204:609-623.
9. Mammen A.L. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011, 7:343-354.
10. Christopher-Stine L. Statin myopathy: an update. Curr Opin Rheumatol 2006, 18:647-653.
11. Hoogendijk J.E., Amato A.A., Lecky B.R., et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:337-345.
12. Hilton-Jones D., Miller A., Parton M., Holton J., Sewry C., Hanna M.G. Inclusion body myositis. MRC centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010, 20:142-147.
13. De Bleecker J.L., De Paepe B., Van Walleghem I.E., Schroeder J.M. Differential expression of chemokines in inflammatory myopathies. Neurology 2002, 58:1779-1785.
14. Creus K.K., De Paepe B., De Bleecker J.L. Idiopathic inflammatory myopathies and the classical NF-kB complex: current insights and implications for therapy. Autoimm Rev 2009, 8:627-631.
15. Bronner I.M., Linssen W.H.J.P., van der Meulen M.F.G., et al. Polymyositis - An ongoing discussion about a disease entity. Arch Neurol 2004, 61:132-135.
16. Amato A.A., Griggs R.C. Unicorns, dragons, polymyositis, and other mythical beasts. Neurology 2003, 61:288-290.
17. Prokop S., Heppner F.L., Goebel H.H., Stenzel W. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am J Pathol 2011, 178:1279-1286.
18. Mammen A.L., Gaudet D., Brisson D., et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase- associated autoimmune myopathy. Arthr Care Res 2012, 64:1233-1237.
19. Schroeder N.W.J., Goebel H.H., Brandis A., Ladhoff A.M., Heppner F.L., Stenzel W. Pipestem capillaries in necrotizing myopathy revisited. Neuromusc Disord 2013, 23:66-74.
20. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 2011, 23:595-604.
21. Wedderburn L.R., Varsani H., Charles K.C., et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: A tool for potential use in clinical trials. Arthr Rheum 2007, 57:1192-1201.
22. Fasth A.E.R., Dastmalchi M., Rahbar A., et al. T cell infiltrates in the muscle of patients with dermatomyositis and polymyositis are dominated by CD28(null) T cells. J Immunol 2009, 183:4792-4799.
23. Goebel H., Stenzel W. Practical application of electron microscopy to neuromuscular diseases. Ultrastr Pathol 2013, 37:15-18.
24. Gitiaux C., Kostallari E., Lafuste P., Authier F.J., Christov C., Gherardi R.K. Whole microvascular unit deletions in dermatomyositis. Ann Rheum Dis 2013, 72:445-452.
25. Dimitri D. Inflammatory myopathies: diagnosis and classifications. Press Médicale 2009, 38:1141-1163.
26. Gallardo E., Rojas-Garcia R., de Luna N., Pou A., Brown R.H., Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001, 57:2136-2138.
27. Gallardo E., de Luna N., Diaz-Manera J., et al. Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy. PlosOne 2011, 6:e29061.
28. Casciola-Rosen L., Mammen A.L. Myositis autoantibodies. Curr Opin Rheumatol 2012, 24:602-608.
29. Stanciu R., Guiguet M., Musset L., et al. Antisynthetase syndrome with Anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol 2012, 39:1835-1839.
30. Khan S., Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin N Am 2011, 37:143-158.
31. De Paepe B., Creus K.K., De Bleecker J.L. Chemokine profile of the different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann NY Acad Sci 2007, 1109:441-453.